Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis
10.3760/cma.j.issn.1673-4408.2017.02.007
- VernacularTitle:托珠单抗治疗全身型幼年特发性关节炎的疗效和安全性
- Author:
Yandie LI
- Keywords:
Tocilizumab;
Systemic juvenile idiopathic arthritis;
Interleukin-6;
Efficacy;
Safety
- From:
International Journal of Pediatrics
2017;44(2):99-103
- CountryChina
- Language:Chinese
-
Abstract:
Juvenile idiopathic arthritis (JIA)is one of the most common chronic rheumatic diseases in childhood.Systemic juvenile idiopathic arthritis(SJIA) is a subtype of JIA,which may be different from other subtypes.As shown in studies,interleukin-6 (IL-6),IL-18,IFN-γ,may instead of TNF-α,play an important role in SJIA.Traditional biological agents such as TNF antagonists have limited effect in the patients with SJIA.Tocilizumab(TCZ),a humanized anti-IL-6 receptor monoclonal antibody,inhibits the binding of IL-6 with transmembrane IL-6R or soluble IL-6R,blocking the IL-6 mediated inflammation and joint destruction.This article reviews the efficacy and safety of TCZ in patients with SJIA.
